Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods.

Allison Avrich CieslaRyan E WiegandZachary R SmithAmadea BrittonKatherine E Fleming-DutraJoseph MillerEmma K AccorsiJennifer R VeraniNong ShangGordana DeradoTamara PilishviliRuth Link-Gelles

Published in: Open forum infectious diseases (2023)

Monovalent mRNA booster doses provided additional protection against symptomatic SARS-CoV-2 infection during BA.2/BA.2.12.1 and BA.4/BA.5 subvariant circulation, but protection waned over time.

Keyphrases

respiratory syndrome coronavirus
sars cov
coronavirus disease
young adults
randomized controlled trial
systematic review
binding protein